IVBT (Innovation1 Biotech) Retained Earnings: $-59.57 Mil (As of Feb. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech Retained Earnings?

Innovation1 Biotech IVBT 12 Retained Earnings is $-59.57 Mil as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Innovation1 Biotech's retained earnings for the quarter that ended in Feb. 2024 was $-59.57 Mil.

Innovation1 Biotech's quarterly retained earnings declined from Aug. 2023 ($-58.63 Mil) to Nov. 2023 ($-59.05 Mil) and declined from Nov. 2023 ($-59.05 Mil) to Feb. 2024 ($-59.57 Mil).

Innovation1 Biotech's annual retained earnings declined from Aug. 2021 ($-2.97 Mil) to Aug. 2022 ($-44.55 Mil) and declined from Aug. 2022 ($-44.55 Mil) to Aug. 2023 ($-58.63 Mil).


Innovation1 Biotech  (OTCPK:IVBT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Innovation1 Biotech Retained Earnings Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech Retained Earnings Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -1.21 -3.84 -2.97 -44.55 -58.63

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.43 -53.95 -58.63 -59.05 -59.57
IVBT
12GF Score
Innovation1 Biotech Inc IVBT
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-59.57 Mil mean?
Innovation1 Biotech (IVBT) has a Retained Earnings of $-59.57 Mil as of Feb. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Innovation1 Biotech and its competitors.
Is Innovation1 Biotech's Retained Earnings too high?
Innovation1 Biotech's current Retained Earnings is $-59.57 Mil. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's Retained Earnings compare to NVIV and PXMD?
Innovation1 Biotech's Retained Earnings of $-59.57 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Diversified Financial Services company?
A good Retained Earnings depends on the Diversified Financial Services industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Innovation1 Biotech and its competitors. Innovation1 Biotech's current Retained Earnings is $-59.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current Retained Earnings of $-59.57 Mil. The current Retained Earnings is $-59.57 Mil. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current Retained Earnings is $-59.57 Mil as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price